Fig. 5: Determination of ecto-GPR37 in CSF of patients with parkinsonism.
From: GPR37 processing in neurodegeneration: a potential marker for Parkinson’s Disease progression rate
A Screening of ecto-GPR37 levels in cerebrospinal fluid (CSF) from neurological controls (NCs) and patients with Parkinson’s disease (PD), multiple system atrophy (MSA), corticobasal degeneration (CBD) and progressive supranuclear palsy (PSP). *P < 0.05 vs NC, Student’s t-test. ROC curve analysis of CSF ecto-GPR37 comparing NC with PD (B), MSA (C), CBD (D) and PSP (E) subjects. The Area Under the Curve (AUC) and the p-value is indicated for each ROC curve.
